Current Environment: Production

Eitan Rubinstein | Education

Undergraduate School

University of California San Diego

1999, San Diego, CA

Medical School

University of Southern California School of Medicine

2003, Los Angeles, CA

Internship

Pediatric Primary Care

Boston Combined Residency Program (BCRP)

2004, Boston, MA

Residency

Pediatric Primary Care Track

Boston Combined Residency Program (BCRP)

2006, Boston, MA

Fellowship

Pediatric Gastroenterology, Hepatology, and Nutrition

University of California

2010, San Diego, CA

Eitan Rubinstein | Certifications

  • American Board of Pediatrics (Gastroenterology)

Eitan Rubinstein | Publications

  1. The role of dupilumab in the treatment of eosinophilic esophagitis. Immunotherapy. 2024; 16(13):845-852. View The role of dupilumab in the treatment of eosinophilic esophagitis. Abstract

  2. Characterization of Eosinophilic Esophagitis in Infants and Toddlers. J Pediatr Gastroenterol Nutr. 2023 07 01; 77(1):86-92. View Characterization of Eosinophilic Esophagitis in Infants and Toddlers. Abstract

  3. Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center. JPGN Rep. 2022 May; 3(2):e180. View Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center. Abstract

  4. Oral viscous mometasone is an effective treatment for eosinophilic esophagitis. J Allergy Clin Immunol Pract. 2020 Mar; 8(3):1107-1109. View Oral viscous mometasone is an effective treatment for eosinophilic esophagitis. Abstract

  5. Respiratory symptoms associated with eosinophilic esophagitis. Pediatr Pulmonol. 2018 11; 53(11):1587-1591. View Respiratory symptoms associated with eosinophilic esophagitis. Abstract

  6. Every-other-day Dosing of Oral Viscous Budesonide Is not Effective in the Management of Eosinophlic Esophagitis. J Pediatr Gastroenterol Nutr. 2018 03; 66(3):395-397. View Every-other-day Dosing of Oral Viscous Budesonide Is not Effective in the Management of Eosinophlic Esophagitis. Abstract

  7. Comparison of 2 delivery vehicles for viscous budesonide to treat eosinophilic esophagitis in children. J Pediatr Gastroenterol Nutr. 2014 Sep; 59(3):317-20. View Comparison of 2 delivery vehicles for viscous budesonide to treat eosinophilic esophagitis in children. Abstract

  8. Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency. BMC Gastroenterol. 2014 Apr 09; 14:71. View Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency. Abstract

  9. The utility of endoscopy and multichannel intraluminal impedance testing in children with cough and wheezing. Pediatr Pulmonol. 2014 Nov; 49(11):1090-6. View The utility of endoscopy and multichannel intraluminal impedance testing in children with cough and wheezing. Abstract

  10. Topical inhaled ciclesonide for treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2012 Oct; 130(4):1011; author reply 1011-2. View Topical inhaled ciclesonide for treatment of eosinophilic esophagitis. Abstract

  11. Siglec-F inhibition reduces esophageal eosinophilia and angiogenesis in a mouse model of eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2011 Oct; 53(4):409-16. View Siglec-F inhibition reduces esophageal eosinophilia and angiogenesis in a mouse model of eosinophilic esophagitis. Abstract

  12. Hepatic, cardiovascular, and endocrine outcomes of the histological subphenotypes of nonalcoholic fatty liver disease. Semin Liver Dis. 2008 Nov; 28(4):380-5. View Hepatic, cardiovascular, and endocrine outcomes of the histological subphenotypes of nonalcoholic fatty liver disease. Abstract

BESbswy